Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa

被引:9
作者
Aarts, P. [1 ]
van Huijstee, J. C. [1 ]
van Der Zee, H. H. [1 ]
van Straalen, K. R. [1 ]
Prens, E. P. [1 ]
机构
[1] Erasmus MC, Dept Dermatol, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
关键词
D O I
10.1111/jdv.19725
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Adalimumab monotherapy for hidradenitis suppurativa (HS) is often insufficient with a maximum clinical efficacy of 60% in Hidradenitis Suppurativa Clinical Response (HiSCR) and limited effect on draining tunnels. Data suggest that adalimumab therapy could be improved by concomitant antibiotics.Objective: To compare the clinical effectiveness of adalimumab with clindamycin and rifampicin versus adalimumab monotherapy after 12 weeks.Methods: This retrospective study included patients who started adalimumab with additional clindamycin and rifampicin and patients treated with adalimumab monotherapy, matched on sex and refined Hurley score. The primary outcome measure was the difference in change in the International Hidradenitis Suppurativa Severity Score System (IHS4) at 12 weeks.Results: In total, 62 patients were included in the combination therapy group (n = 31) and adalimumab monotherapy group (n = 31), showing comparable IHS4 scores; 32.5 versus 29, p = 0.87 at baseline respectively. The combination therapy demonstrated greater clinical effectiveness expressed in median IHS4 improvement (-20 vs. -9, p < 0.001), IHS4-55 (74% vs. 36%, p = 0.002), median draining tunnel reduction (-4 vs. -2, p < 0.001) and pain response (47% vs. 27%, p = 0.02).Conclusion: Adalimumab initiated with clindamycin and rifampicin shows greater clinical effectiveness than adalimumab monotherapy. An important difference in effect was observed in the decrease of draining tunnels, addressing a serious limitation of adalimumab monotherapy.
引用
收藏
页码:904 / 909
页数:6
相关论文
共 23 条
[1]   Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting [J].
Aarts, Pim ;
van Huijstee, Johanna C. ;
van der Zee, Hessel H. ;
van Doorn, Martijn B. A. ;
van Straalen, Kelsey R. ;
Prens, Errol P. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (04) :677-684
[2]   North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management [J].
Alikhan, Ali ;
Sayed, Christopher ;
Alavi, Afsaneh ;
Alhusayen, Raed ;
Brassard, Alain ;
Burkhart, Craig ;
Crowell, Karen ;
Eisen, Daniel B. ;
Gottlieb, Alice B. ;
Hamzavi, Iltefat ;
Hazen, Paul G. ;
Jaleel, Tara ;
Kimball, Alexa B. ;
Kirby, Joslyn ;
Lowes, Michelle A. ;
Micheletti, Robert ;
Miller, Angela ;
Naik, Haley B. ;
Orgill, Dennis ;
Poulin, Yves .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) :91-101
[3]   Clindamycin Mono-Therapy of Hidradenitis Suppurativa Patients: A Single-Center Retrospective Study [J].
An, Ji Hae ;
Moon, Su Jin ;
Shin, Jung U. ;
Kim, Dong Hyun ;
Yoon, Moon Soo ;
Lee, Hee Jung .
ANNALS OF DERMATOLOGY, 2021, 33 (06) :515-521
[4]   Biofilm production and antibiotic susceptibility of Staphylococcus epidermidis strains from Hidradenitis Suppurativa lesions [J].
Ardon, C. B. ;
Prens, E. P. ;
Fuursted, K. ;
Ejaz, R. N. ;
Shailes, J. ;
Jenssen, H. ;
Jemec, G. B. E. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (01) :170-177
[5]   Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatogy Life Quality Index (DLQI): Further Data [J].
Basra, M. K. A. ;
Salek, M. S. ;
Camilleri, L. ;
Sturkey, R. ;
Finlay, A. Y. .
DERMATOLOGY, 2015, 230 (01) :27-33
[6]  
Del Rosso JQ, 2010, CUTIS, V85, P15
[7]   Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab [J].
Frew, J. W. ;
Jiang, C. S. ;
Singh, N. ;
Grand, D. ;
Navrazhina, K. ;
Vaughan, R. ;
Krueger, J. G. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2021, 46 (02) :306-313
[8]   Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study [J].
Gulliver, W. ;
Alavi, A. ;
Wiseman, M. C. ;
Gooderham, M. J. ;
Rao, J. ;
Alam, M. S. ;
Papp, K. A. ;
Desjardins, O. ;
Jean, C. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (12) :2431-2439
[9]   Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study [J].
Hafner, A. ;
Ghislain, P. D. ;
Kovacs, R. ;
Batchelor, R. ;
Katoulis, A. C. ;
Kirby, B. ;
Banayan, H. ;
Schonbrun, M. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (11) :2277-2284
[10]   Hurley Staging Refined: A Proposal by the Dutch Hidradenitis Suppurativa Expert Group [J].
Horvath, Barbara ;
Janse, Ineke C. ;
Blok, Janine L. ;
Driessen, Rieke J. B. ;
Boer, Jurr ;
Mekkes, Jan R. ;
Prens, Errol P. ;
Van Der Zee, Hessel H. .
ACTA DERMATO-VENEREOLOGICA, 2017, 97 (03) :412-413